However, the market for gastrointestinal disorder therapeutics will decline in that period, due to negative growth of the gastroesophageal reflux disease therapeutics as patents lapse and more drugs become generic.
Patent expirations of major drugs have increased competition, driving further consolidation and more use of licensing agreements.
Related Articles on Gastrointestinal Drugs:
10 Recent Studies and Breakthroughs Impacting Gastroenterology/Endoscopy
PPI Use in GI Treatment May Increase Risk of Fractures, Infections
Experimental Colon Cancer Drug Shows Effectiveness in Trial
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
